Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Phosphagenics — Investor Presentation (September 2017)
14 slides from Avecho Biotechnology's investor presentation, Sep 26, 2017
Slide 1: Entitlement Offer Presentation
September 2017 Entitlement Offer Presentation TPM® : World leading delivery technology www.phosphagenics.com (ASX : POH)
Slide 2: Cautionary statements
Cautionary statements Nature of this document This presentation has been prepared by Phosphagenics Limited (Phosphagenics, POH or Company) in relation to a proposed partially underwritten, pro rata non-renounceable entitlement offer (Entitlement Offer) of new shares to be made under section 708AA of
Slide 3: Cautionary statements (cont.)
Cautionary statements (cont.) Not financial product advice This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire new shares and does not and will not form any part of any contract for the acquisition of new
Slide 4: Cautionary statements (cont.)
Cautionary statements (cont.) Forward-Looking Statements This document may contain forward-looking statements. Forward looking statements are only predictions and are subject to risks, uncertainties and assumptions which include (but are not limited to) commodity prices, currency fluctuations, econo
Slide 5: Entitlement Offer overview
Entitlement Offer overview ● Entitlement Offer to raise up to approximately A$4.7 million by way of a partially underwritten, 1 for 4 pro‐rata non‐ renounceable entitlement offer to existing shareholders (Entitlement Offer) Offer Size & Structure ● Up to 315,491,490 new POH shares (New Shares) to be
Slide 6: Sources and uses of funds - $4.7m cash raised
Sources and uses of funds - $4.7m cash raised This table displays the intended use of funds if the maximum of $4.7m is raised Sources $m Uses $m Cash balance at 31 August 2017 3.024 Mylan arbitration 1.7 Continue the development and R&D rebate 1.195 partnership of the TPM Opioid 2.4 Patches Cash rai
Slide 7: Sources and uses of funds - $3m cash raised
Sources and uses of funds - $3m cash raised This table displays intended use of funds if $3m is raised (approximately 60% of the offer)1 Sources $m Uses $m Cash balance at 31 August 2017 3.024 Mylan arbitration 1.7 Continue the development and R&D rebate 1.195 partnership of the TPM Opioid 2.4 Patch
Slide 8: Entitlement Offer Timetable
Entitlement Offer Timetable Date (AEST1 unless otherwise stated) Announcement of Entitlement Offer Tuesday, 26 September 2017 POH Shares begin to trade on an “ex‐entitlement” basis Friday, 29 September 2017 Record Date for determining Eligible Shareholders under the Entitlement Offer Monday, 2 Octob
Slide 9: Post entitlement issue capital structure
Post entitlement issue capital structure Pre Raising Post Raising (assuming Post Raising (assuming $4.7m is raised) $3m is raised) Shares 1.261 Billion 1.577 Billion 1.461 Billion Cash and R&D rebate $4.219M (August 2017) $8.919M $7.219M Market Cap (at $0.018) $22.7M $28.4M $26.3M 9
Slide 10: Risks of Rights Issue
Risks of Rights Issue Mylan arbitration The Mylan arbitration remains a substantial focus for Phosphagenics in 2017. Both the TPM®/ Daptomycin product itself, and the damages Phosphagenics is seeking, represent significant value potential for the company and contribute to the ongoing protection of t
Slide 11: Risks of Rights Issue
Risks of Rights Issue Healthcare funding and reimbursement Level of market acceptance of the company’s products is dependent to some degree on levels of reimbursement from governments and private health insurers for the use of the company’s products. If the level of expected funding is not received,
Slide 12: Risks of Rights Issue
Risks of Rights Issue Reliance on Partners and Commercial Agreements Phosphagenics relies on its partnership with Terumo Corporation and has recently signed an Oxymorphone Development Agreement with Terumo Corporation. However, negotiations in relation to a definitive sale or licensing agreement con
Slide 13: International offer restrictions
International offer restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any
Slide 14: Melbourne Office contact details
www.phosphagenics.com Melbourne Office Unit A8, 2A Westall Road Dr Ross Murdoch, CEO & Managing Director Hallmarc Business Park rmurdoch@phosphagenics.com Clayton VIC 3168 Australia Tel: +61 3 9002 5000 Email: info@phosphagenics.com Investor Relations Questions Kyahn Williamson WE Buchan Tel: +61 3
Phosphagenics — Investor Presentation (September 2017) on 6ix